Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nitish K Dhingra

Showing results (41-50 of 56) with videos related to

Pageof 6
Sort By:
The Annals of Thoracic Surgery|October 18, 2025
Trends and Outcomes of Mechanical Circulatory Support in Acute Myocardial Infarction and Cardiogenic Shock Patients Undergoing Coronary Artery Bypass GraftingKevin R An, Lamia Harik, Mohamed Rahouma, et al.
The Canadian Journal of Cardiology|January 25, 2022
Leaflet Resection vs Preservation for Degenerative Mitral Regurgitation: Functional Outcomes and Mitral Stenosis at 12 Months in a Randomized TrialMakoto Hibino, Arjun Pandey, Vincent Chan, et al.
JTCVS Techniques|April 17, 2025
How I do it ─ superficial parasternal intercostal plane catheter insertionJuan F Morales, Michael J Ricci, Subodh Verma, et al.
Journal of Clinical Medicine|July 27, 2024
Patient Reported Outcome Measures in Adults with Fontan Circulatory FailureGuillermo Agorrody, Isaac Begun, Subodh Verma, et al.
The Journal of Thoracic and Cardiovascular Surgery|October 27, 2021
Mitral repair with leaflet preservation versus leaflet resection and ventricular reverse remodeling from a randomized trialMakoto Hibino, Nitish K Dhingra, Subodh Verma, et al.
The Lancet. Diabetes & Endocrinology|December 3, 2021
Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trialSubodh Verma, Nitish K Dhingra, Javed Butler, et al.
The Canadian Journal of Cardiology|November 2, 2025
When Bad Things Happen to Good Hearts; Prediction and Management of Primary Graft DysfunctionNitish K Dhingra, Farid Foroutan, Lauren K Truby, et al.
Circulation|November 7, 2022
Empagliflozin in Black Versus White Patients With Heart Failure: Analysis of EMPEROR-PooledSubodh Verma, Nitish K Dhingra, Javed Butler, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|May 18, 2023
Presence of Peripheral Artery Disease Is Associated With Increased Risk of Heart Failure Events: Insights From EMPEROR-PooledSubodh Verma, Nitish K Dhingra, Marc P Bonaca, et al.
JACC. Heart Failure|September 16, 2023
Efficacy and Safety of Empagliflozin According to Background Diuretic Use in HFrEF: Post-Hoc Analysis of EMPEROR-ReducedNitish K Dhingra, Subodh Verma, Javed Butler, et al.
Pageof 6

Showing results (41-50 of 56) with videos related to

Sort By:
Pageof 6
The Annals of Thoracic Surgery|October 18, 2025
Trends and Outcomes of Mechanical Circulatory Support in Acute Myocardial Infarction and Cardiogenic Shock Patients Undergoing Coronary Artery Bypass GraftingKevin R An, Lamia Harik, Mohamed Rahouma, et al.
The Canadian Journal of Cardiology|January 25, 2022
Leaflet Resection vs Preservation for Degenerative Mitral Regurgitation: Functional Outcomes and Mitral Stenosis at 12 Months in a Randomized TrialMakoto Hibino, Arjun Pandey, Vincent Chan, et al.
JTCVS Techniques|April 17, 2025
How I do it ─ superficial parasternal intercostal plane catheter insertionJuan F Morales, Michael J Ricci, Subodh Verma, et al.
Journal of Clinical Medicine|July 27, 2024
Patient Reported Outcome Measures in Adults with Fontan Circulatory FailureGuillermo Agorrody, Isaac Begun, Subodh Verma, et al.
The Journal of Thoracic and Cardiovascular Surgery|October 27, 2021
Mitral repair with leaflet preservation versus leaflet resection and ventricular reverse remodeling from a randomized trialMakoto Hibino, Nitish K Dhingra, Subodh Verma, et al.
The Lancet. Diabetes & Endocrinology|December 3, 2021
Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trialSubodh Verma, Nitish K Dhingra, Javed Butler, et al.
The Canadian Journal of Cardiology|November 2, 2025
When Bad Things Happen to Good Hearts; Prediction and Management of Primary Graft DysfunctionNitish K Dhingra, Farid Foroutan, Lauren K Truby, et al.
Circulation|November 7, 2022
Empagliflozin in Black Versus White Patients With Heart Failure: Analysis of EMPEROR-PooledSubodh Verma, Nitish K Dhingra, Javed Butler, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|May 18, 2023
Presence of Peripheral Artery Disease Is Associated With Increased Risk of Heart Failure Events: Insights From EMPEROR-PooledSubodh Verma, Nitish K Dhingra, Marc P Bonaca, et al.
JACC. Heart Failure|September 16, 2023
Efficacy and Safety of Empagliflozin According to Background Diuretic Use in HFrEF: Post-Hoc Analysis of EMPEROR-ReducedNitish K Dhingra, Subodh Verma, Javed Butler, et al.
Pageof 6